GPCR
HealthcareStructure Therapeutics Inc. · Biotechnology · $2B
What is Structure Therapeutics Inc.?
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule drugs for chronic diseases with significant unmet medical need.
The company designs oral small molecule therapeutics that target G-protein-coupled receptors (GPCRs). Its lead program targets the GLP-1 receptor for type-2 diabetes and obesity. Additional pipeline candidates address pulmonary arterial hypertension and idiopathic pulmonary fibrosis, conditions with few effective oral treatment options.
Founded in 2016 and headquartered in South San Francisco, California.
- GSBR-1290 – oral GLP-1 receptor agonist for obesity and type-2 diabetes
- ANPA-0073 – apelin receptor agonist targeting pulmonary and cardiovascular disease
- LTSE-2578 – LPA1 receptor antagonist for idiopathic pulmonary fibrosis
Is GPCR a Good Stock to Buy?
UQS Score rates GPCR as Poor overall.
Among the five pillars, Risk comes in at a Neutral rating — reflecting a profile that, while uncertain, is not the weakest dimension of the company's current standing.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue clinical-stage company. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the full pillar breakdown and financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GPCR pay dividends?
No — Structure Therapeutics Inc. does not currently pay a dividend.
Structure Therapeutics does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions.
When does GPCR report earnings?
Structure Therapeutics reports financial results on a quarterly cadence, typical for US-listed companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, pipeline milestones, and operating expenses rather than revenue or profitability metrics.
For the most recent results and upcoming reporting dates, visit Structure Therapeutics' investor relations page directly.
GPCR Price History
+83.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Structure Therapeutics Inc.?
Based on Structure Therapeutics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Structure Therapeutics do?
Structure Therapeutics develops oral small molecule drugs that target GPCRs — a class of receptors involved in metabolic and pulmonary diseases. Its lead candidate targets the GLP-1 receptor for obesity and type-2 diabetes, placing it in one of the most competitive therapeutic areas in biopharma.
Does GPCR pay dividends?
No. Structure Therapeutics does not pay a dividend. The company is in the clinical stage with no commercial revenue, so capital is reinvested into drug development and clinical programs rather than returned to shareholders.
When does GPCR report earnings?
Structure Therapeutics follows a standard quarterly reporting schedule. Our data source does not provide specific upcoming dates — check the company's investor relations page for the latest schedule.
Is GPCR a good stock to buy?
UQS Score rates GPCR as Poor overall, with Weak readings across Quality, Moat, and Growth pillars and an Elevated Valuation. This profile reflects the high-risk, high-uncertainty nature of clinical-stage biotech investing. Pro members can view the complete pillar breakdown.
Is GPCR overvalued?
The UQS Valuation pillar for GPCR is rated Elevated. For a pre-revenue company, valuation is largely driven by pipeline potential and market expectations rather than current financials. The full valuation analysis is available to Pro members.
Is GPCR a long-term quality indicator?
From a long-term quality standpoint, GPCR's current UQS profile — with Weak Quality and Moat scores — reflects the early-stage nature of the business. Long-term prospects depend heavily on clinical trial outcomes and the company's ability to build durable competitive advantages over time.
What sector does GPCR belong to?
Structure Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on oral small molecule drugs for metabolic and pulmonary diseases, targeting a validated class of drug receptors known as GPCRs.
Who founded Structure Therapeutics?
Structure Therapeutics was founded in 2016 and was formerly known as ShouTi Inc. Detailed founding information, including founder names, is publicly available through the company's official disclosures and investor relations materials.
Unlock Full GPCR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for GPCR
- ✓Access detailed financial metrics and trend data
- ✓Compare GPCR against clinical-stage peers in the Healthcare sector
- ✓Get the full risk and valuation assessment in one place
Pro Analysis
GPCR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 12.5 | 0.0 | 12.0 | 2.4 | 60.0 | 0.0 | +0.5 |
| May 9, 2026 | 12.0 | 0.0 | 12.0 | 0.0 | 60.0 | 0.0 | +1.5 |
| Apr 22, 2026 | 10.5 | 0.0 | 12.0 | 2.4 | 47.1 | 0.0 | -0.2 |
| Apr 2, 2026 | 10.7 | 0.0 | 12.0 | 3.0 | 47.1 | 0.0 | — |
GPCR — Pillar Breakdown
Quality
— 0.0/100 (25%)Structure Therapeutics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 2.4/100 (20%)Structure Therapeutics Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 60.0/100 (15%)Structure Therapeutics Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Structure Therapeutics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 12/100 (25%)Structure Therapeutics Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GPCR.
Score Composition
Financial Data
More Stock Analysis
How is the GPCR UQS Score Calculated?
The UQS (Unified Quality Score) for Structure Therapeutics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Structure Therapeutics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Structure Therapeutics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.